<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03603340</url>
  </required_header>
  <id_info>
    <org_study_id>2017-02332f</org_study_id>
    <nct_id>NCT03603340</nct_id>
  </id_info>
  <brief_title>The ESTxENDS Trial- Effects of Using Electronic Nicotine Delivery Systems (ENDS/Vaporizer/E-cig) on Depression</brief_title>
  <acronym>ESTxENDS</acronym>
  <official_title>Efficacy, Safety and Toxicology of Electronic Nicotine Delivery Systems as an Aid for Smoking Cessation (ESTxENDS Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Lausanne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Geneva, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>State Hospital, St. Gallen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Krebsforschung Schweiz, Bern, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federal Office of Public Health, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Bern</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cigarette smoking is the leading cause of preventable death in Switzerland and still more&#xD;
      than a quarter of the Swiss population smokes cigarettes. Smoking and depression are strongly&#xD;
      associated. Individuals with depression are twice as likely to be smokers than persons&#xD;
      without a depression. Studies have shown that attempts to quit tobacco smoking are more&#xD;
      likely to fail for individuals with depression than without. Depressive symptoms are common&#xD;
      in prolonged nicotine withdrawal and individuals with depression are more nicotine dependent&#xD;
      and more likely to suffer depressive symptoms during nicotine withdrawal compared to smokers&#xD;
      in the general population.&#xD;
&#xD;
      Recently, electronic nicotine delivery systems (ENDS; also called vaporizer or electronic&#xD;
      cigarette) have become popular with smokers who want to stop smoking or reduce their exposure&#xD;
      to inhaled chemicals since ENDS use appears to be safer than tobacco smoking. ENDS with&#xD;
      nicotine containing e-liquids may be effective in assisting with tobacco smoking cessation&#xD;
      without suffering depressive symptoms.&#xD;
&#xD;
      This study will therefore test the efficacy of ENDS for cigarette smoking cessation, the&#xD;
      safety of ENDS on adverse events and the effect of ENDS on health-related outcomes such as&#xD;
      depression and exposure to inhaled chemicals.&#xD;
&#xD;
      For this trial, cigarette smokers motivated to quit smoking cigarettes will be included.&#xD;
      Participants in the intervention group will receive an ENDS and nicotine-containing&#xD;
      e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive&#xD;
      smoking cessation counseling. Participants in the control group will receive smoking&#xD;
      cessation counseling only. All participants will be followed over a 24-month period. Presence&#xD;
      and severity of depression will be assessed using the 9-question depression scale from the&#xD;
      patient health questionnaire (PHQ-9) at baseline and at 6, 12 and 24 months' follow-up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2018</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Statisticians and laboratory personnel will be blinded to group allocation</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of severity of self-reported symptoms of depression_1</measure>
    <time_frame>6 months post quit date</time_frame>
    <description>Measured using the 9-question depression scale from the patient health questionnaire (PHQ-9). The PHQ-9 is it is used to monitor the severity of depression. The PHQ-9 is the depression module, which scores each of the nine DSM-IV criteria as &quot;0&quot; (not at all) to &quot;3&quot; (nearly every day).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of severity of self-reported symptoms of depression_2</measure>
    <time_frame>12 months post quit date</time_frame>
    <description>Measured using the 9-question depression scale from the patient health questionnaire (PHQ-9). The PHQ-9 is it is used to monitor the severity of depression. The PHQ-9 is the depression module, which scores each of the nine DSM-IV criteria as &quot;0&quot; (not at all) to &quot;3&quot; (nearly every day).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of severity of self-reported symptoms of depression_3</measure>
    <time_frame>24 months post quit date</time_frame>
    <description>Measured using the 9-question depression scale from the patient health questionnaire (PHQ-9). The PHQ-9 is it is used to monitor the severity of depression. The PHQ-9 is the depression module, which scores each of the nine DSM-IV criteria as &quot;0&quot; (not at all) to &quot;3&quot; (nearly every day).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of change of severity of self-reported symptoms of depression</measure>
    <time_frame>Change from baseline to 6,12, 24 months post quit date</time_frame>
    <description>Measured using the 9-question depression scale from the patient health questionnaire (PHQ-9). The PHQ-9 is it is used to monitor the severity of depression. The PHQ-9 is the depression module, which scores each of the nine DSM-IV criteria as &quot;0&quot; (not at all) to &quot;3&quot; (nearly every day).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1172</enrollment>
  <condition>Smoking Cessation</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ENDS (vaporizer/e-cig) and smoking cessation counseling</intervention_name>
    <description>Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Smoking cessation counseling</intervention_name>
    <description>Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Informed Consent as documented by signature&#xD;
&#xD;
          -  Persons aged 18 or older&#xD;
&#xD;
          -  Currently smoking 5 or more cigarettes a day for at least 12 months&#xD;
&#xD;
          -  Willing to try to quit smoking within the next 3 months,&#xD;
&#xD;
          -  Persons providing a valid phone number, a valid email address and/or a valid postal&#xD;
             address.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Known hypersensitivity or allergy to contents of the e-liquid&#xD;
&#xD;
          -  Participation in another study with investigational drug within the 30 days preceding&#xD;
             the baseline visit and during the present study where interactions are to be expected&#xD;
&#xD;
          -  Women who are pregnant or breast feeding&#xD;
&#xD;
          -  Intention to become pregnant during the course of the scheduled study intervention,&#xD;
             i.e. within the first 6-months of the study&#xD;
&#xD;
          -  Persons having used ENDS or tobacco heating systems regularly in the 3 months&#xD;
             preceding the baseline visit&#xD;
&#xD;
          -  Persons having used nicotine replacement therapy (NRT) or other medications with&#xD;
             demonstrated efficacy as an aid for smoking cessation such as varenicline or bupropion&#xD;
             within the 3 months preceding the baseline visit&#xD;
&#xD;
          -  Persons who cannot attend the 6- month follow-up visit for any reason&#xD;
&#xD;
          -  Cannot understand instructions delivered in person or by phone, or otherwise unable to&#xD;
             participate in study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reto Auer, Prof.Dr.med</last_name>
    <role>Study Director</role>
    <affiliation>Berner Institut für Hausarztmedizin (BIHAM)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reto Auer, Prof.Dr.med</last_name>
    <phone>+41 31 631 58 79</phone>
    <email>reto.auer@biham.unibe.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Schöni, Dr.</last_name>
    <phone>+41 31 631 58 66</phone>
    <email>anna.schoeni@biham.unibe.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Unisanté, Centre universitaire de médecine générale et santé publique, Université de Lausanne</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan Berlin, Prof.Dr.med</last_name>
      <email>ivan.berlin@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinic for General Internal Medicine, Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Rodondi, Prof.Dr.med</last_name>
      <email>Nicolas.Rodondi@insel.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Département de médecine interne, Hôpitaux universitaires de Genève</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Paul Humair, PD Dr.med.</last_name>
      <email>Jean-Paul.Humair@hcuge.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lungenzentrum, Klinik für Pneumologie und Schlafmedizin, Kantonsspital St. Gallen</name>
      <address>
        <city>Saint Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Brutsche, Prof.Dr.med.</last_name>
      <email>Martin.Brutsche@kssg.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anja Frei, Dr.</last_name>
      <email>anja.frei@uzh.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Hall SM, Humfleet GL, Muñoz RF, Reus VI, Robbins JA, Prochaska JJ. Extended treatment of older cigarette smokers. Addiction. 2009 Jun;104(6):1043-52. doi: 10.1111/j.1360-0443.2009.02548.x. Epub 2009 Apr 9. Erratum in: Addiction. 2011 Jun;106(6):1204.</citation>
    <PMID>19392908</PMID>
  </reference>
  <reference>
    <citation>Kalman D, Morissette SB, George TP. Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict. 2005 Mar-Apr;14(2):106-23. Review.</citation>
    <PMID>16019961</PMID>
  </reference>
  <reference>
    <citation>Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: A population-based prevalence study. JAMA. 2000 Nov 22-29;284(20):2606-10.</citation>
    <PMID>11086367</PMID>
  </reference>
  <reference>
    <citation>Ziedonis D, Hitsman B, Beckham JC, Zvolensky M, Adler LE, Audrain-McGovern J, Breslau N, Brown RA, George TP, Williams J, Calhoun PS, Riley WT. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine Tob Res. 2008 Dec;10(12):1691-715. doi: 10.1080/14622200802443569.</citation>
    <PMID>19023823</PMID>
  </reference>
  <reference>
    <citation>Glassman AH. Cigarette smoking: implications for psychiatric illness. Am J Psychiatry. 1993 Apr;150(4):546-53. Review.</citation>
    <PMID>8465868</PMID>
  </reference>
  <reference>
    <citation>Weinberger AH, Pilver CE, Desai RA, Mazure CM, McKee SA. The relationship of major depressive disorder and gender to changes in smoking for current and former smokers: longitudinal evaluation in the US population. Addiction. 2012 Oct;107(10):1847-56. doi: 10.1111/j.1360-0443.2012.03889.x. Epub 2012 May 17.</citation>
    <PMID>22429388</PMID>
  </reference>
  <reference>
    <citation>Bolam B, West R, Gunnell D. Does smoking cessation cause depression and anxiety? Findings from the ATTEMPT cohort. Nicotine Tob Res. 2011 Mar;13(3):209-14. doi: 10.1093/ntr/ntq244. Epub 2011 Feb 17.</citation>
    <PMID>21330275</PMID>
  </reference>
  <reference>
    <citation>Gierisch JM, Bastian LA, Calhoun PS, McDuffie JR, Williams JW Jr. Smoking cessation interventions for patients with depression: a systematic review and meta-analysis. J Gen Intern Med. 2012 Mar;27(3):351-60. doi: 10.1007/s11606-011-1915-2. Epub 2011 Oct 26. Review.</citation>
    <PMID>22038468</PMID>
  </reference>
  <reference>
    <citation>Weinberger AH, Mazure CM, Morlett A, McKee SA. Two decades of smoking cessation treatment research on smokers with depression: 1990-2010. Nicotine Tob Res. 2013 Jun;15(6):1014-31. doi: 10.1093/ntr/nts213. Epub 2012 Oct 25. Review.</citation>
    <PMID>23100459</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 2, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>October 24, 2020</last_update_submitted>
  <last_update_submitted_qc>October 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

